Drug Trial Radar · NCT02204644
The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML
Last checked: Nov 19, 2026Latest source record: Feb 27, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Jun 2014
Primary completion
Jun 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to observe the efficacy and the safety of Flumatinib vs Imatinib as first line treatment in patients with newly diagnosed chronic phase chronic myelogenous leukemia. Randomized,Open Label,Control
Conditions
- CML, CML-CP,MMR,TKI
Interventions
Flumatinib 600mg qdDrug
Imatinib 400mg qdDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- SIX-month major molecular response rateTime frame: six months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of Blood Diseases, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.